Gastrointestinal drugs companies in the Asia-Pacific region focus on developing medications for the treatment of gastrointestinal disorders. These companies contribute to gastroenterology by providing pharmaceutical solutions for conditions such as acid reflux, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD), enhancing digestive health.
Latest Asia-Pacific Gastrointestinal Drugs Companies Updates:
Dec 2023
Takeda Pharmaceutical Company Limited Launched their Entyvio® (vedolizumab) for the treatment of ulcerative colitis in China, expanding their market reach in the region.Partnered with research institutions in Japan to develop AI-powered tools for early diagnosis and personalized treatment of GI diseases.
Eisai Received regulatory approval for their Halaven® (erituximab) for the treatment of advanced gastric cancer in South Korea, offering a new treatment option for patients.Collaborated with healthcare providers in Southeast Asia to improve access to GI medications and raise awareness about GI health management.
AstraZeneca Presented positive Phase III data on their Nexium® (esomeprazole) for the prevention of esophageal recurrence in Barrett's esophagus patients in China, strengthening their position in the acid reflux management market.Partnered with government agencies in India to implement public health education programs on GI health and disease prevention.
Sanofi S.A. Introduced their Zetia® (ezetimibe) in combination with Zocor® (simvastatin) for the treatment of high cholesterol in Japan, targeting a broader patient population.Focused on expanding their portfolio of GI medications and digital health solutions in the Asia-Pacific region.
Johnson & Johnson Announced the development of a novel oral medication for the treatment of ulcerative colitis, aimed at offering a more convenient and patient-friendly treatment option.Collaborated with startups and technology companies to develop innovative diagnostic tools and digital platforms for personalized GI care.
List of Asia-Pacific Gastrointestinal Drugs Key companies in the market
The Asia-Pacific gastrointestinal drugs market is expected to reach USD 14,868 Million by 2030 at 8.60% CAGR during the forecast period 2022-2030.Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world. Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.
Gastrointestinal diseases has gained a tremendous attention over the last few years. Owing to increasing prevalence of different gastrointestinal diseases and disorders, encouraged many companies for initiating the research in the development of innovative and advanced drugs. Furthermore, increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development drives the growth of the Asia-Pacific gastrointestinal drugs market. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the Asia-Pacific gastrointestinal drugs market growth.
From the few last decades, the government of Asian countries have been educating the people about the various diseases and their treatment availability. Relief International, with funding from the European Union, is working with Bangladesh citizens to implement One Health Asia, a program designed to prevent zoonotic diseases through training and education. Many organizations and companies are conducting surveys and programs to educate the peoples about the diseases and treatment.
Ageing, decreases the immunity of the body and increases the probability of diseases. According to Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia likely to help the growth of the Asia-Pacific gastrointestinal drugs market over the forecast period.
On the other hand, the presence of misbranded & spurious drugs, and unavailability of lifelong cure may hinder the Asia-Pacific gastrointestinal drugs market growth over the review period.
Research Methodology 
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation
Segmentation The Asia-Pacific gastrointestinal drugs market is segmented on the basis of drug class and type of disease.
On the basis of drug class, Asia-Pacific gastrointestinal drugs market is segmented into acid neutralizers, laxatives & antidiarrheal, antiemetics, antiulcer, and others.
On the basis of type of disease, Asia-Pacific gastrointestinal drugs market is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.Figure: Asia-Pacific Gastrointestinal Drugs Market, by Region, 2016 (%) 
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation
Regional Analysis
Asia gastrointestinal drugs market is segmented on the basis of region: China, India, Republic of Korea, and Rest of Asia. Japan accounts for the major share of the market owning to the well-developed technology and high healthcare expenditure. People in this region are more focused on health, which drive the growth of the market. China is the second largest market, which is followed by India. Owing to the government support for the research & development, well-developed healthcare infrastructure, and high health care expenditure drive the China gastrointestinal drugs market. India is the fastest growing gastrointestinal drugs market across the region. Increasing need for the better treatment methods rapidly changing the healthcare sector. Additionally, the presence of huge opportunities for the development of the market have boosted the market growth.
Developing nations, for instance, India is experiencing high demand for gastrointestinal disorder drugs. Major pharmaceuticals drug manufacturers are using their technology and services to develop new drugs for gastrointestinal diseases to meet the growing demand.
Key Players Some of the key players in Asia-Pacific gastrointestinal drugs market are Abbott, Allergan Plc, AstraZeneca, Eli lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals, and others.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)